AddedRisk Factors
In November 2025, we acquired all the outstanding shares of Baergic. The acquisition provided global rights to AZD7325 (AXS-17), an oral GABAA receptor α2,3 subtype-selective PAM, originally licensed from AstraZeneca AB (AZ), for the potential treatment of epilepsy. We also assumed the AZD7325 license agreement between Baergic and AZ. The total upfront payment was $2.3 million, and the former Baergic shareholders and AZ are also eligible to receive contingent development, regulatory and sales-based milestone payments of up to $159.5 million and tiered low double-digit to mid-teen royalties on potential global net sales of AZD7325.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedRisk Factors
In December 2025, we acquired the global rights to deuterium-stabilized S-bupropion from DeuteRx. DeuteRx is eligible to receive contingent development, regulatory and sales-based milestones of up to $523 million and a tiered low single-digit royalty on potential global net sales.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedRisk Factors
There are also federal and state laws on marketing and solicitation, such as CAN-SPAM. The CAN-SPAM Act, among other things, obligates the sender of commercial emails to provide recipients with the ability to opt out of receiving future commercial emails from the sender. Any failure by us to comply fully with the CAN-SPAM Act may leave us subject to substantial fines and penalties.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedRisk Factors
In addition, foreign jurisdictions, such as Canada, have enacted laws that regulate our ability to send commercial messages via email. For example, Canada’s Anti-Spam Legislation (“CASL”) prohibits email marketing without the recipient’s consent, with limited exceptions. The penalties for non-compliance with CASL are considerable, including administrative monetary penalties of up to $10 million and a private right of action.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RemovedRisk Factors
In September 2020, we entered into a Loan and Security Agreement, or the Loan Agreement, for a term loan, which we refer to as the 2020 Term Loan, with Hercules Capital, Inc., or Hercules, in its capacity as administrative agent and collateral agent and as a lender, and the other financial institutions that from time to time become parties to the Loan Agreement, collectively referred to as the Lenders, secured by a lien on substantially all of our assets, including intellectual property. In October 2021, we entered into a First Amendment to the Loan Agreement to, among other things, increase the size of the 2020 Term Loan. In March 2022, we entered into a Second Amendment to the Loan Agreement that, among other things, changed the terms of the Term Loan Advances (as defined in the Loan Agreement) upon the consummation of the Acquisition (as defined in the Loan Agreement). In January 2023, we entered into the Third Amendment, which amended the terms of the Loan Agreement to, among other things, increase the size of the aggregate principal amount under the 2020 Term Loan from $300.0 million to $350.0 million, reduce the interest rate, and extend the maturity and interest-only period of the Loan Agreement. In May 2023, we entered into the Fourth Amendment, which increased the amount of cash that could be held by the Malta Subsidiary outside of the United States and waived any purported default with respect to the amount of cash held by the Malta Subsidiary prior to the date of the Fourth Amendment. In August 2023, Hercules granted Axsome a waiver to the Fourth Amendment, increasing the amount of cash that could be held by the Malta Subsidiary outside of the United States until December 31, 2023. In September 30, 2024, we entered into the Fifth Amendment, which amended the terms of the Loan Agreement to, among other things: (i) increase the size of the aggregate principal amount under tranche 3 of the 2020 Term Loan from $75.0 to $80.0 million; (ii) extend the availability periods of certain tranches of the 2020 Term Loan; (iii) alter the terms of the performance covenants contained in the Loan Agreement and also add a new performance covenant; (iv) conditionally waive the minimum cash requirement during such periods of time that Axsome’s market capitalization exceeds $1.5 billion; and (v) permit the Malta Subsidiary to request an advance from the Lenders up to a certain amount to the extent that Axsome may request an advance in such amount and to increase the amount of cash that the Malta Subsidiary may hold outside of the United States, as set forth in greater detail in the Fifth Amendment.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedRisk Factors
In addition, on October 7, 2023, Hamas militants and members of other terrorist organizations infiltrated Israel’s southern border from the Gaza Strip and conducted a series of terror attacks on civilian and military targets. Shortly following the attack, Israel’s security cabinet declared war against Hamas, and Israel launched an aerial bombardment of various targets within the Gaza Strip and then also began ground operations in the Gaza Strip, which remain ongoing. Other terrorist and/or regional organizations have joined the hostilities as well, including Hezbollah in Lebanon, and the Houthis in Yemen, and it is possible that other countries in the Middle East, including Iran, will become further involved in hostilities with Israel, resulting in a further widening of the conflict. The intensity and duration of Israel’s current wars are difficult to predict as are such wars’ implications for the global economy.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedRisk Factors
General political uncertainty may have an adverse impact on our operating performance and results of operations. In particular, the U.S. continues to experience significant political events that cast uncertainty on global financial and economic markets, especially following the recent presidential election. It is presently unclear exactly what actions the second Trump administration in the U.S. will implement, and if implemented, how these actions may impact the biopharmaceutical industry in the U.S. Any actions taken by the Trump administration, including the many recent executive orders, may have a negative impact on the U.S. economy and on our business, financial condition, and results of operations.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedRisk Factors
•stricter harmonized EU rules on data privacy particularly in relation to personal data, including health data, than is the case in the United States which are being further toughened with the EU General Data Protection Regulation, or the GDPR, which became enforceable beginning May 25, 2018;
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedRisk Factors
In the EU, recently adopted and pending legislation will impact regulatory procedures for medicinal products. Key developments include Regulation (EU) 2021/2282 on health technology assessment (HTA Regulation), which became applicable in the EU on 12 January 2025. Additionally, in April 2023, the EC adopted a proposal to revise the EU pharmaceutical legislation consisting of a new directive and a new regulation that would replace Directive 2001/83/EC and Regulation (EC) 726/2004, among others. In April 2024, the European Parliament introduced amendments to the EC’s proposal. The EU legislative process remains ongoing, with several stages still required before the reform can receive final approval. If approved, the reform would mark the most significant overhaul of EU pharmaceutical law since 2004, with a wide range of impacts including on approval procedures, regulatory data protection, or RDP, and the so-called “Bolar exemption,” among others.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RewordedRisk Factors
For instance, Furthermore, although we believe that we are able to rely on the Phase 2 CONCERT trial trial, Phase 3 SYMPHONY trial, and SYMPHONY Phase 3 ENCORE trial to support an NDA for AXS-12 for the treatment of cataplexy and narcolepsy and the completed Phase 2 trial and Phase 3 trial to support an NDA for AXS-14 for the management of fibromyalgia, narcolepsy, the FDA could still require additional studies to support the approval of an NDA for these this and other product candidates.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although we submitted NDAs to the FDA for Auvelity AUVELITY (which was approved) and for Symbravo for the acute treatment of migraines SYMBRAVO (which received a CRL complete response letter (CRL) and has now been approved), approved) and for AXS-14 (which received a Refuse to File letter from the FDA, and which we plan to resubmit), we have not otherwise submitted an NDA to the FDA, or similar drug approval filings to comparable foreign authorities, for any product candidate, and we cannot be certain that our current or future product candidates will be successful in clinical trials or receive regulatory approval.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
Even if physicians prescribe our products, third-party payors may not provide coverage or coverage, such as if they may not consider them our products cost effective without a significant price concession, and, even when coverage is provided, may not provide adequate reimbursement, which in each such case could negatively impact our revenue.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, because patent applications take time to publish and can take many years to issue, and because there is no way to guarantee we are aware of all third party patents and applications, there may be currently pending applications, unknown to us, which may later result in issued patents that any of our current or future products may infringe.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability, including in South America, ongoing military conflicts between Russia and Ukraine Ukraine, hostilities in the Middle East and between Israel and Hamas, Hezbollah, and the Houthis, elsewhere and record inflation.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
In January 2025, the previously-published However, it remains in draft guidance was removed from the FDA website, form, which may impact impacts the eventual publication date of the final guidance, and as a result, may delay the compliance deadline.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
Recent court decisions have impacted the FDA’s enforcement activity regarding off-label promotion in light of First Amendment considerations; however, there are still significant risks in this area area, such as where communications are misleading or conduct is the alleged cause of false claims, in part due to the potential FCA exposure.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. protection, or that we may choose not to pursue patent protection for all patentable aspects identified.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
In the United States, engaging in the impermissible promotion of our products, following approval, for off-label uses can also subject us to false claims and other litigation under federal and state statutes, including fraud and abuse and consumer protection laws, which can lead to civil and criminal penalties penalties, damages, fines, and fines, actions, agreements with governmental authorities that materially restrict the manner in which we promote or distribute drug products and do business through, for example, corporate integrity agreements, suspension or exclusion from participation in federal and state healthcare programs, and suspension or debarment from government contracts procurement and refusal of potential adverse actions affecting future orders under existing contracts.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
If the government or third-party payors fail to provide adequate coverage and payment rates reimbursement for any of our products, or if such payors and health care providers including health maintenance organizations (HMOs) and long-term care facilities facilities, choose to use therapies that are less expensive, our products may lose or fail to generate potential revenue and our prospects for profitability may be limited.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
Additionally, as more fully described in “Business—Material License Agreements,” Agreements, we are required to pay to an entity owned by our Chief Executive Officer and Chairman of the Board certain royalty payments related to the any sales of the Company’s Auvelity AUVELITY product / AXS-05 portfolio product, as well as two product candidates that are not currently in active development.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedRisk Factors
Prior to our commercialization of Auvelity AUVELITY and Sunosi SUNOSI in 2022, and the recent approval and U.S. commercialization of Symbravo, SYMBRAVO in 2025, we had not obtained marketing approvals for any product candidates, manufactured products on a commercial scale or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful commercialization.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Under the FCA, a penalty may be imposed for each false claim, which, for example, might be a claim for payment for each prescription for the product, and, when aggregated, these penalties often total millions of dollars and incentivize qui tam lawsuits.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
We are a biopharmaceutical company dedicated to the development and commercialization of innovative medicines for people impacted by central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and developing differentiated medicines with a focus on novel mechanisms of action that have the potential to transform patient outcomes.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
Our broad commercial portfolio is comprised of AUVELITY, SUNOSI, and SYMBRAVO. AUVELITY is the first and only oral NMDA receptor antagonist approved by the FDA for the treatment of MDD in adults, which we are further developing in additional psychiatric conditions, including Alzheimer’s disease agitation. SUNOSI is the first and only DNRI approved by the FDA for the treatment of excessive daytime sleepiness associated with obstructive sleep apnea and narcolepsy, for which we also receive royalty revenue associated with sales in out-licensed territories. SYMBRAVO is approved by the FDA for the acute treatment of migraine in adults with or without aura, which we recently launched in the U.S. We are also advancing a pipeline of novel product candidates addressing a broad range of serious neurological and psychiatric conditions, including narcolepsy, fibromyalgia, and ADHD. Refer to Part I, Item 1. “Business” for a summary of our marketed products and clinical development programs.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
To determine whether acquisitions should be accounted for as an acquisition of a business or as an acquisition of an asset, we make certain judgments, which include evaluating whether the acquired set of activities and assets would meet the definition of a business. If, based upon our evaluation, we determine that the inputs, processes, and outputs associated with the acquired set of activities and assets in a transaction include an input and a substantive process that together significantly contribute to the ability to create outputs, the transaction is treated as an acquisition of a business. If we determine that substantially all of the fair value of assets acquired in a transaction is concentrated in a single asset or a group of similar assets, the transaction is treated as an acquisition of assets.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
An acquisition of a business is accounted for under the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at their fair values as of the acquisition date. Significant judgments and estimates are used in determining the fair value of assets acquired and liabilities assumed. The fair values of identifiable intangible assets related to currently marketed products are determined by using an income approach, through which fair value is estimated based on each asset’s discounted projected net cash flows. Inputs used in the projected cash flows include historical and projected pricing, the underlying asset patent life, our ability to manufacture and commercialize the asset, the ability to obtain regulatory approvals and the extent and timing of potential new product introductions by competitors in the marketplace. An acquisition of a business also can include the potential for future payment of consideration that is contingent upon the achievement of certain milestones, including royalty payments on future product sales. The fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. Consideration in excess over the fair value of net assets acquired is recorded as goodwill.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
If the acquired set of activities and assets does not meet the definition of a business, the acquisition is treated as an acquisition of an asset. In an acquisition of an asset, in-process research and development (IPR&D) projects are recorded as research and development expense at the acquisition date unless there is an alternative future use, no goodwill is recorded, and contingent consideration relating to development, regulatory and commercial milestones are not recognized at the acquisition date and instead are recorded when it is probable they will occur and can be reasonably estimated.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
On February 21, 2023, we entered into a Sublease with Advance Magazine Publishers d/b/a Conde Nast for the entirety of the twenty-second floor of One World Trade Center in New York, NY, or the Sublease.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
As described below in the “Loan Agreement with Blackstone” section, on May 8, 2025, we entered into the Blackstone Loan Agreement with Blackstone, certain subsidiaries of our party thereto as guarantors, Wilmington Trust, and the Lenders. The Blackstone Loan Agreement provides for Loans in an aggregate principal amount of up to $570.0 million. Further, we entered into a securities purchase agreement with Blackstone, and its affiliates, for the private placement (the “Private Placement”) of an aggregate of 140,000 shares of our common stock, at a purchase price of $107.14 per share. Gross proceeds from the Private Placement were approximately $15.0 million. The closing of the Private Placement occurred contemporaneously with the closing of the Blackstone Loan Agreement.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
On May 8, 2025, we repaid in full our obligations under the Hercules Loan Agreement using proceeds from the Blackstone Loan Agreement. As of December 31, 2025, there are no outstanding obligations under the Hercules Loan Agreement.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
In November 2025, we acquired all the outstanding shares of Baergic. The acquisition provided global rights to AZD7325 (AXS-17), an oral GABAA receptor α2,3 subtype-selective PAM, originally licensed from AstraZeneca AB (AZ), for the potential treatment of epilepsy. We also assumed the AZD7325 license agreement between Baergic and AZ. The total upfront payment was $2.3 million, and the former Baergic shareholders and AZ are also eligible to receive contingent development, regulatory and sales-based milestone payments of up to $159.5 million and tiered low double-digit to mid-teen royalties on potential global net sales of AZD7325.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
In December 2025, we acquired the global rights to deuterium-stabilized S-bupropion from DeuteRx. DeuteRx is eligible to receive contingent development, regulatory and sales-based milestones of up to $523 million and a tiered low single-digit royalty on potential global net sales.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
On the Closing Date, we entered into the Blackstone Loan Agreement with Blackstone, certain subsidiaries of ours party thereto as guarantors, Wilmington Trust, and the Lenders, providing for loans in an aggregate principal amount of up to $570.0 million, consisting of (i) a first lien senior secured term loan in an aggregate principal amount of $120.0 million funded to us on the Closing Date, (ii) a $180.0 million senior secured term loan which is available to us at our option, of which $90.0 million is available to us until May 31, 2026, and of which the remaining $90.0 million is available until May 31, 2027 (the “Term Loans”) and (iii) a super senior revolving credit facility in an aggregate principal amount of up to $70.0 million available at our option (the “Revolver” and collectively with the Term Loans, the “Loans”). The Blackstone Loan Agreement also permits us, subject to the consent of the Lenders, to request incremental term loans in an aggregate principal amount of up to $200.0 million at any time and on the same terms as the initial Term Loans, except that any call protection will be determined at the time the incremental term loans are incurred. The proceeds of the Term Loans were used, together with cash on hand, to repay in full our obligations under the Hercules Loan Agreement, which resulted in a recording of a loss on debt extinguishment of approximately $10.4 million in the Company’s consolidated statement of operations. The Term Loans bear interest at a variable SOFR plus 4.75%. The Revolver bears interest at SOFR plus 4.0%. The maturity date of the Loans is May 8, 2030. The Blackstone Loan Agreement provides for additional drawdowns at our option, subject to certain conditions, and includes customary covenants and a minimum liquidity covenant of $30.0 million. The obligations under the Blackstone Loan Agreement are secured by a first lien on certain assets of ours and our subsidiaries.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
AddedMD&A
On May 8, 2025, we repaid in full our obligations under the Hercules Loan Agreement using proceeds from the Blackstone Loan Agreement. As of December 31, 2025, there are no outstanding obligations under the Hercules Loan Agreement.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RemovedMD&A
We are a biopharmaceutical company leading a new era in the treatment of CNS disorders. We deliver scientific breakthroughs by identifying critical gaps in care and developing differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our CNS portfolio includes multiple FDA-approved products that are being further developed for additional neurological or psychiatric conditions and novel product candidates in late-stage clinical development. In May 2022, we completed the U.S. acquisition of Sunosi from Jazz and in November 2022, we acquired the ex-U.S. assets of Sunosi from Jazz for certain international markets. Sunosi is a product approved by the FDA and marketed in the U.S. to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea, and also approved in Europe in January 2020 by the European Commission. In August 2022, Auvelity® was approved by the FDA for the treatment of MDD in adults and we initiated the commercial launch of Auvelity in the U.S. in October 2022. In January 2025, Symbravo® was approved by the FDA for the acute treatment of migraine with or without aura in adults. Refer to Part I, Item 1. “Business” for a summary of our clinical programs.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
We recognize the grant date fair value of the stock options over the requisite service period, which is generally the vesting term. For awards only subject to service-based vesting conditions, we elected to recognize stock-based compensation expense on a straight-line basis.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
In January 2023, we entered into a Third Amendment to the Loan Agreement, or the Third Amendment, with Hercules. The Third Amendment increased the size of the Term Loan Advance (as defined in the Loan Agreement) to $350.0 million, reduces the interest rate, and extends the maturity and interest-only period of the Loan Agreement. In September 2024, we entered into a Fifth Amendment to the Loan Agreement, or the Fifth Amendment, with Hercules. The Fifth Amendment amended the terms of the Loan Agreement to, among other things: (i) increase the size of the aggregate principal amount under tranche 3 of the 2020 Term Loan (as defined below) from $75.0 to $80.0 million; (ii) extend the availability periods of certain tranches of the 2020 Term Loan; (iii) alter the terms of the performance covenants contained in the Loan Agreement and also add a new performance covenant; (iv) conditionally waive the minimum cash requirement during such periods of time that Axsome’s market capitalization exceeds $1.5 billion; and (v) permit Axsome Malta Ltd., or the Malta Subsidiary, to request an advance from the Lenders (as defined in the Loan Agreement) up to a certain amount to the extent that Axsome may request an advance in such amount and to increase the amount of cash that the Malta Subsidiary may hold outside of the United States, as set forth in greater detail in the Fifth Amendment. We drew down upon tranche 1C of the 2020 Term Loan, and as of December 31, 2024, we had approximately $180 million outstanding and $150 million remaining under the 2020 Term Loan. See the “Contractual Obligations and Commitments – January 2023 Third Amendment to the Loan and Security Agreement – Hercules”, “Contractual Obligations and Commitments – September 2024 Fifth Amendment to the Loan and Security Agreement – Hercules” sections below, and Note 10. Loan and Security Agreement for more information.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
Capitalized terms used but not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
On September 30, 2024, we entered into the Fifth Amendment. The Fifth Amendment amended the terms of the Loan Agreement to, among other things: (i) increase the Tranche 3 Commitment from $75.0 to $80.0 million; (ii) extend the availability periods of Tranche 1D to June 15, 2025 and that of Tranche 1E to December 15, 2025, as set forth in greater detail in the Fifth Amendment; (iii) alter the terms of Performance Covenant A, Performance Covenant B, and Performance Covenant C and also add a Performance Covenant D, as set forth in greater detail in the Fifth Amendment; (iv) conditionally waive the requirement that the Company maintain Qualified Cash in an amount greater than or equal to the sum of $30.0 million plus the Qualified Cash A/P Amount at all times during such periods of time that the Company’s Market Capitalization exceeds $1.5 billion; and (v) permit the Malta Subsidiary, to request an Advance from the Lenders up to a certain amount to the extent that the Company may request an Advance in such amount and to increase the amount of Cash that the Malta Subsidiary may hold outside of the United States, as set forth in greater detail in the Fifth Amendment.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
On May 8, 2023, we entered into the Waiver and Fourth Amendment to the Loan Agreement, or the Fourth Amendment, with Hercules, in its capacity as administrative agent and collateral agent, and the Lenders. The Fourth Amendment increased the amount of Cash that could be held by the Malta Subsidiary outside of the United States from $3.0 million to $15.0 million for a 45-day period after the closing of the Fourth Amendment and to $10.0 million thereafter. The Fourth Amendment also waived any purported default with respect to the amount of cash held by the Malta Subsidiary prior to the date of the Fourth Amendment. In August 2023, Hercules granted Axsome a waiver to the Fourth Amendment, permitting the Malta Subsidiary to hold up to $12.5 million in Cash outside of the United States until December 31, 2023.
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
The Third Amendment amended the terms of the Loan Agreement to, among other things:
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
•Extend the maturity date to January 1, 2028, unless the Company meets certain revenue targets as described in the Loan Agreement, in which case the Company can extend the maturity date to January 1, 2029;
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
•Increase the aggregate principal amount under the Loan Agreement from $300.0 million to $350.0 million;
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
•Subject to the terms and conditions in the Loan Agreement, change the term loan advance amounts and availability dates under the Tranche 1 Advance through Tranche 5 Advance, including increasing the Tranche 1 Advance from one tranche of $95.0 million to five sub-tranches of $95.0 million, $55.0 million, $30.0 million, $35.0 million, and $35.0 million, respectively, changing the Tranche 2 Advance from three sub-tranches of $35.0 million, $35.0 million, and $30.0 million, respectively, to one tranche of $25.0 million, changing the Tranche 3 Advance from two sub-tranches of $15.0 million and $5.0 million, respectively, to one tranche of $75.0 million, and removing the Tranche 4 Advance and Tranche 5 Advance entirely;
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
•Revise the interest rate applicable to extensions of credit under the Loan Agreement to equal (a) if the prime rate is greater than or equal to 7.00%, the greater of either (i) the prime rate plus 2.20%, and (ii) 9.95%, but in no event greater than 10.70%, and (b) if the prime rate is less than 7.00%, 9.70%;
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RemovedMD&A
•Increase the minimum cash requirement of the Company to the sum of $30.0 million plus the Qualified Cash A/P Amount; and
Read it in 10-K Feb 18, 2025 at sec.govopen_in_new
RewordedMD&A
In March 2022, we entered into a sales agreement, agreement with Leerink, or the March 2022 Sales Agreement with Leerink, and filed a prospectus supplement, pursuant to which we may sell up to $200 million in shares of our common stock from time to time through Leerink, acting as our sales agent, in one or more at-the-market offerings utilizing the 2019 Shelf Registration Statement. supplement.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
The increase decrease was primarily related due to greater higher net product revenues from AUVELITY and SUNOSI, which was partially offset by higher selling, general and administrative expenses from commercial activities for Auvelity AUVELITY, including a national direct-to-consumer advertising campaign and Sunosi, sales force expansion, the commercial launch of SYMBRAVO, and higher personnel costs related to organizational growth, including non-cash stock-based compensation.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Cost of revenue (excluding amortization and depreciation) 47,478 33,303 26,065 Research and development 183,279 187,077 97,944 Selling, general and administrative 570,599 411,359 323,123 Loss (Gain) in fair value of contingent consideration (2,473) 28,124 48,918 Intangible asset amortization 6,375 6,392 6,375 Total operating expenses 805,258 666,255 502,425 Loss from operations (166,762) (280,562) (231,825) Interest expense, net (6,557) (6,569) (6,453) Loss on debt extinguishment (10,385) — Loss before income taxes (183,704) (287,131) (238,278) Income tax expense benefit (expense) 530 (85) (960) Net loss $ (183,174) $ (287,216) $ (239,238) Net loss per common share, basic and diluted $ (3.68) $ (5.99) $ (5.27) Weighted average common shares outstanding, basic and diluted 49,747,178 47,914,253 45,425,212
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
We expect selling, general and administrative anticipate SG&A expenses to increase in 2026 as we expand marketing, promotional, increase marketing and advertising costs promotional spending for Auvelity AUVELITY and Sunosi, continue launch Symbravo, and to support general administrative needs. for SYMBRAVO.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
The $2.5 million change for the year ended December 31, 2025, as compared to a $28.1 million change for the year ended December 31, 2024, as compared to a $48.9 million change for the year ended December 31, 2023 2024 was primarily related to changes in significant unobservable inputs, including discount rates, and significant assumptions, including future sales estimates.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Cost of revenue was $47.5 million for the year ended December 31, 2025, as compared to $33.3 million for the year ended December 31, 2024, as compared to $26.1 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
Selling, general and administrative expenses were $570.6 million for the year ended December 31, 2025, as compared to $411.4 million for the year ended December 31, 2024, as compared to $323.1 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
For the year ended December 31, 2024, we We recognized royalty revenue of $4.7 million and $3.5 million for the years ended December 31, 2025 and 2024, respectively, related to Pharmanovia’s sales of Sunosi. SUNOSI.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
In December 2022, Also in connection with the 2022 2025 Shelf Registration Statement, we filed a new sales agreement prospectus to replace the prior prospectus supplement filed in August 2022 associated with the December 2022, which would have expired 2019 Shelf Registration Statement. in December 2025.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
The increase was primarily related to greater higher commercial activities for Auvelity AUVELITY, including a national direct-to-consumer advertising campaign and Sunosi, sales force expansion, the commercial launch of SYMBRAVO, and higher personnel costs related to organizational growth, including non-cash stock-based compensation.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
We generated $381.7 total revenues of $638.5 million and $202.5 $385.7 million in net revenue from product sales for the years ended December 31, 2024 2025 and 2023, 2024, respectively.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
RewordedMD&A
For the year ended December 31, 2024, 2025, we received approximately $40.8 $52.9 million in gross proceeds through the sale of 466,108 451,176 shares, of which net proceeds were approximately $40.0 million, under the March 2022 Sales Agreement. $51.9 million.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
Quiet changesMD&A
Selling, general and administrative expenses primarily consist of salaries and related costs for personnel in executive, commercial, finance, and operational functions, including stock-based compensation and travel expenses.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new
Quiet changesMD&A
We have recorded a valuation allowance on against substantially all of our deferred tax assets.
Read it in 10-K Feb 23, 2026 at sec.govopen_in_new